PHASE3

Medtech is the 'other' side of life sciences we'll be looking hard at in 2025. So we're watching the new BioMelbourne Network-led Australian Medtech Manufacturing Alliance's latest steps with interest. It launched only a few months ago off the back of several years of work by Shelley Jackson. Clinical life sciences - the sexy biotech stuff - has traditionally got all of the attention in Australia. Medtech is difficult as it requires making things and Australia is deeply insecure about its ability to do that in any sector, let alone medical products. The upshot? This new industry group hopes to bring the country's growing medtech sector into the light, and inject some confidence into the local consciousness that yes, it is possible to make stuff in Australia. Read about the latest moves here: https://lnkd.in/gNVgRCBV And catch up on your PHASE3 listening here: https://lnkd.in/gB8P4MJz #medtech #medtechnews #amma Pathology Technology Australia MTPConnect Association of Healthcare Supply and Procurement Officers Medical Technology Association of Australia (MTAA) AusBiotech Claudia Loeber-Raab

We're constantly intrigued by the idea of open medicine research. In recent news from the charity-led side of biotech, the Open Medicine Foundation has raised enough cash to start a large ME/CFS biomarker study. It is set to start a large scale study measuring more than 10,000 proteins and metabolites from stored blood samples donated 1200 patients, to identify a biomarker that can be found via a blood test. The upshot? Researchers have been looking for biomarkers for chronic fatigue syndrome for years, and one team from Stanford University School of Medicine developed a blood test in 2019. But with Long COVID making the condition infamous, the momentum is finally here to get something done. Read about the new biomarker study here: https://lnkd.in/eGZEqrXS And catch up on your PHASE3 listening here: https://lnkd.in/gB8P4MJz #longcovid #CFS #biotech #medtech #openmedicine

If COVID19 taught us that we *can* test for respiratory infections at home, the next epidemic - Mpox - is ground zero for a new type of diagnostic tool. A Boston University-led research team created an optical biosensor for the illness that is spreading in Africa. These use different light wavelengths to detect virus-antibody nanoparticles within 20 minutes of taking a sample. Compare that to days or weeks for a PCR blood test. The upshot? It's obvious really: simple tech that can diagnose infectious disease super fast means treatment starts earlier, and the spread is reduced. Read more about it here: https://lnkd.in/gWwSNyca And catch up on your PHASE3 listening here: https://lnkd.in/gB8P4MJz #mpox #podcast #biotech #medtech #biotechnews #medtechnews

It's not brain-machine interfaces, but it's at one of the cutting edges of energy design: QUT-led researchers have developed an ultra-thin, flexible film that could power next-generation wearable devices using body heat, eliminating the need for batteries. Team leader Professor Zhi-Gang Chen says the breakthrough effectively turns the temperature difference between the human body and surrounding air into electricity. The upshot? Turning minute differences in heat or light into energy is a research area to watch. Clever people are taking their skills in renewable energy, cutting edge battery science, and powering satellites, and putting them to the service of human bodies. Watch this space. Read more about the QUT breakthrough here: https://lnkd.in/gcyZurvY And catch up on your PHASE3 listening here: https://lnkd.in/gB8P4MJz

As we head into Christmas and get set for 2025, PHASE3 will start bringing you tidbits from what we're looking at for next year and throwbacks from our hit series in 2024. The first thing to catch our eye was this nugget from the Mayo Clinic, released today: Although we might be living longer, the gap between the number of years we live in good health (our healthspan) and our lifespan is getting bigger. Globally, that gap is now 9.6 years. In Australia it's 12.1 years and in New Zealand it's 11.8 years. Women have a healthspan-lifespan gap that is 2.4 years wider than men. The upshot? In the race for longevity, the healthspan-lifespan gap is a universal threat. Check it out here: https://lnkd.in/g44YuUDu And catch up on your PHASE3 listening here: https://lnkd.in/gB8P4MJz

Delighted to share my views on cancer vaccines in this final episode of the VAXXED podcast with Rachel Williamson. It was also insightful to hear from Jeannie Joughin PhD, GAICD partner at OneVentures who explains why investors are showing renewed interest in this space. It’s an exciting time. The science and our understanding of the immune system is evolving rapidly, which I hope will lead to innovative immunotherapies for the benefit of patients. #Frenchtech #biotechnews #cancernews #vaccine #innovation

💉 The final episode of VAXXED is live 💉 This is the last episode of our series on cancer vaccines. It's The Investor and the Chief Executive of the biotech most likely to land the first approved therapy vaccine in recent times. OneVentures partner Dr Jeannie Joughin PhD, GAICD explains why investors like her are excited for the future. And OSE Immunotherapeutics CEO Nicolas Poirier says if his company can deliver the first cancer vaccine this decade, it'll open doors for the whole field. Like all independent media, we survive and thrive on your support. So please – listen, follow, engage, and if you can, donate ❤️ >> Listen https://bit.ly/4fzc32a >> Watch Phase III on YouTube https://lnkd.in/gr634wH3 >> Follow Phase III on LinkedIn and subscribe to our email newsletter https://bit.ly/3WUBgwZ >> Donate (via the ‘Support’ button) and/or subscribe to Phase III https://bit.ly/4cnfwhO #biotech #vaccine #health #cancer #podcast #media #australia

Here's a wild thought: market researchers think cancer vaccines could be worth $US30-40 billion in a decade, but OneVentures venture partner Dr Jeannie Joughin PhD, GAICD says the market might be *underestimating* the opportunity. Tune in on Wednesday morning to our final episode of VAXXED, and the final episode for 2024. Like all independent media, we survive and thrive on your support. So please – listen, follow, engage, and if you can, donate ❤️ >> Listen https://bit.ly/4fzc32a >> Watch Phase III on YouTube https://lnkd.in/gr634wH3 >> Follow Phase III on LinkedIn and subscribe to our email newsletter https://bit.ly/3WUBgwZ >> Donate (via the ‘Support’ button) and/or subscribe to Phase III https://bit.ly/4cnfwhO #biotech #vaccine #health #cancer #podcast #media #australia

One of the details I wasn't able to fit into this week's edition of Phase III was the latest mRNA saga involving CSL. If the federal government got it wrong in passing over CSL as a mRNA COVID19 vaccine maker for Moderna's $2bn pitch, what it might have got right was the $19 million investment in BASE Facility as a source of the material for researchers and clinical trials. Listen in to episode 4 of VAXXED for Seth Cheetham's intriguing account of how they started in COVID19 and shifted to cancer. Like all independent media, we survive and thrive on your support. So please – listen, follow, engage, and if you can, donate ❤️ >> Listen https://bit.ly/4fzc32a >> Watch Phase III on YouTube https://lnkd.in/gr634wH3 >> Follow Phase III on LinkedIn and subscribe to our email newsletter https://bit.ly/3WUBgwZ >> Donate (via the ‘Support’ button) and/or subscribe to Phase III https://bit.ly/4cnfwhO #biotech #vaccine #health #cancer #podcast #media #australia

💉 Episode 4 of VAXXED is live 💉 Cancer vaccines are an area that anyone who is anyone is getting into, but it's a field led largely by academics, not-for–profits, and specialist researchers. So this week we go back to basics - science that is. Australia may not have many cancer vaccine biotechs but – as we pointed out in episode one with the godfather of cancer vaccines, Dr Ian Frazer – it has heft in its research. Dr Seth Cheetham from the The University of Queensland's BASE Facility, a specialist mRNA manufacturing lab, explains why they went from COVID19 to cancer. And Dr Shalin Naik from the WEHI (Walter and Eliza Hall Institute of Medical Research) explains why he's bringing back a spectre of the past, and why he believes it could be the winner of this biotechnology cage match. Like all independent media, we survive and thrive on your support. So please – listen, follow, engage, and if you can, donate ❤️ >> Listen https://bit.ly/4fzc32a >> Watch Phase III on YouTube https://lnkd.in/gr634wH3 >> Follow Phase III on LinkedIn and subscribe to our email newsletter https://bit.ly/3WUBgwZ >> Donate (via the ‘Support’ button) and/or subscribe to Phase III https://bit.ly/4cnfwhO #biotech #vaccine #health #cancer #podcast #media #australia